Notes
2015 euros
Reference
Mezquita-Raya P, et al. Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain. Diabetes Therapy 8: 401-415, No. 2, Apr 2017. Available from: URL: http://doi.org/10.1007/s13300-017-0239-6
Rights and permissions
About this article
Cite this article
Liraglutide cost effective for T2DM in Spain. PharmacoEcon Outcomes News 778, 24 (2017). https://doi.org/10.1007/s40274-017-4001-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-4001-0